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Local lymph node assay
A B S T R A C T
Background: Medicinal plants are used by a large proportion of the global population as complementary and
alternative medicines. However, little is known about their toxicity. G. africana has been used to treat wounds,
coughs and skin diseases and is used in cosmetic formulations such as lotions and shampoos.
Methods: The acute oral and dermal toxicity potential of G. africana was analyzed after a single administration of
300 and 2000mg/kgbw for acute oral toxicity and 2000mg/kgbw for acute dermal toxicity. Female Sprague-
Dawley rats were used for the acute oral toxicity study whereas both male and female Sprague-Dawley rats were
used for the acute dermal toxicity study. In the Episkin skin irritation test, the irritation potential of G. africana
(concentrate) and G. africana (in-use dilution) extracts were assessed using the Episkin reconstituted human
epidermis. In the dermal sensitization study, female CBA/Ca mice were treated with G. africana concentrations
of 50, 100 and 200mg/ml respectively. The vehicle of choice was dimethylformamide which acted as a control.
Results: The results of the acute oral and dermal toxicity studies revealed that the median lethal dosage (LD50)
for G. africana extract in Sprague-Dawley rats was considered to exceed 2000mg/kgbw. In the irritation test, the
G. africana (concentrate) and G. africana (in-use dilution) extracts were non-irritant on the Episkin reconstituted
human epidermis. In the dermal sensitization study, the stimulation index (SI) values for the mice treated with
the G. africana extract at concentrations of 50, 100 and 200mg/ml/kgbw, when compared to the control group,
were 1.3, 0.9 and 1.3 respectively. The open application of the extract at the various concentrations did not
result in a SI of ≥ 3 in any group. Hence, it did not elicit a hypersensitivity response.
Conclusion: These findings demonstrate that the acute toxicity profile for G. africana is acceptable and can
subsequently be used for single use in the pharmaceutical and cosmetic industries.
1. Introduction
The use of medicinal plants for various ailments, ranging from
minor to chronic, is strongly driven by the increased costs of western
medicines, as well as the side effects often linked to the prolonged usage
of these medicines [1]. In developing countries the use of medicinal
plants has become increasingly important in primary health care, with
an estimated 80% of the global population relying on plant-derived
medicines for the treatment of various diseases [2]. More recently,
natural products have also played a pivotal role in the search for either
new drugs or lead compounds used to develop novel therapeutic agents
for the treatment of various human diseases [3–5]. Despite the wide use
of traditional herbal medicines, only a few have been tested for their
efficacy and safety [6–8]. For this reason, studies looking at the tox-
icological and pharmacological profile of medicinal plants, their ex-
tracts, as well as their formulations have increased dramatically over
the last few years [9].
Galenia africana (G. africana), commonly known as “kraalbos”, is
predominantly found in the Namaqualand, as well as in the Western
and Southern Karoo regions of Southern Africa. Traditionally, the plant
has been used in the treatment of coughs, wounds, tuberculosis, der-
matophytic skin infections, inflammation of the eyes and venereal sores
[10–12]. G. africana was also used by indigenous tribes of Southern
Africa as a component of various cosmetic products such as lotions,
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decoctions and dressings [11]. More recently, the antifungal [13,14]
and anti-mycobacterial [10,15,16] activity of G. africana extracts and
flavonoid fractions has been reported.
Phytochemical screening of G. africana aerial parts have identified
various flavonoids as the major secondary metabolites and these in-
clude (2S)-5,7,2′-trihydroxyflavanone, (E)-3,2′,4′-trihydroxychalcone,
(E)-2′,4′-dihydroxychalcone and (E)-3,2′,4′-trihydroxy-3′-methox-
ychalcone [10,16]. Flavonoids are a group of plant derived compounds
that thought to have numerous properties with significant health ben-
efits. Some of these properties include antibacterial, antiviral, anti-
oxidant, anti-inflammarory and anti-tumor activities [7,17,18]. To
date, “kraalbos” has been reported to have some environmental toxicity
[19] and in vitro immunomodulatory effects [20], but the in vitro safety
of the plant has not been determined. G. africana is being used in the
agricultural sector as a biostimulating agent. It is directly applied to
field crops, fruit trees and grass in order to increase the polyphenolic,
chlorophyll and flavonoid levels. G. africana is also used in the cosmetic
industry in shampoo, lotion, soap and hand wash formulations. It is for
this reason that techniques that increase the concentration of flavonoids
should be incorporated in crops and fruits. With the potential of G.
africana in various agricultural and medical applications the safety of
the plant has to be established.
2. Material and methods
2.1. Test material
G. africana was collected from Komaggas farmers, Komaggas
(29.7987 S, 17.4825 E), Namaqua District, Northern Cape Province.
The formal identification of the plant material used in this study was
done by Mr. F. Weitz (Herbarium, Department of Botany, University of
the Western Cape, Bellville). Voucher specimens are kept in the UWC
herbarium (Vries 1; herb no 6595). The plant was dried for several
weeks to maintain the bioactivity and then passed through a hammer
mill to produce a powdery material (approximately 2–3mm). The
milled plant material was mixed with 80% ethanol, in the maceration
process, to produce a yellow-green to brown-green 20% (w/v) extract
with a pH of 6.9. This was then used as a stock solution. This stock
solution was used either undiluted or diluted in an appropriate vehicle
for the studies described in the following sections. G. africana doses and
concentrations used in these studies were expressed as the ammonium
salt and adjusted for the strength of the stock solution. Chemical ana-
lysis of G. africana revealed that it contained total solids of 1.7% m/m
and a specific gravity of 0.8611. The stock solution was demonstrated
to be stable for at least 48 months at ambient room temperature in the
dark. Dose formulations were generally prepared on the day of use. A
DMA 38 Density Meter (No. 005260) was used to record the G. africana
density of 0.883 g/ml and this value was used in preparing the dose
formulations. Formulation analysis with regard to concentration,
homogeneity and stability was done by Charles River Laboratories
(Tranent, Edinburg, UK). Furthermore, the plant name has been
checked with http://www.theplantlist.org.
2.2. Testing facilities and regulatory compliance
The studies described in the following sections were performed by
Charles River Laboratories (Tranent, Edinburg, UK). All animal ex-
periments were conducted in the P39 room of the toxicology accom-
modation at Charles River. Chemical analysis of the extract was per-
formed at Afriplex (Pty) Ltd. All of the studies were performed
according to OECD Guidelines for the Testing of Chemicals and Good
Laboratory Practices. Study protocols were approved by the testing
facilities’ Institutional Animal Care and Use Committees. Animal hus-
bandry and use were in accordance with applicable local and interna-
tional regulations and guidelines. All animals were supplied by Charles
River UK Limited, Test Facility Study No. 515938 (Kent, UK) and were
allowed to acclimatise to the toxicology housing at these laboratories
for at least 7–8 days before dosing.
2.3. Acute oral toxicity study
The acute oral toxicity test of G. africana extract was evaluated in
mice according to the procedures outlined by the OECD guideline No.
423 [21]. It was conducted to assess the adverse effects which may
result within a short time period following a single oral administration
of G. africana extract. Oral administration was selected as it is a po-
tential route of accidental human exposure and it allows for hazard
classification of test substances. Briefly, nine female (nulliparous and
non-pregnant) Sprague-Dawley rats (6–7 weeks old and 165–177 g)
were used. Animals were allowed to acclimatise to the toxicology ac-
commodation at the laboratories for at least 14 days before dosing. No
formal randomization protocol was followed when allocating them to
groups. G. africana was administered by oral gavage at doses of 300 and
2000mg/kgbw to three groups of three female rats. These doses were
chosen because no adverse effects were seen after the 300mg/kgbw
dose. Hence a higher dose, 2000mg/kgbw was administered to assess
the effect of the extract. Standard conditions were maintained from the
time the animals arrived until the end of the observation period which
included an average of temperature 21 °C; average daily humidity of
36% and 83% (minimum and maximum respectively); a 12 h light/dark
cycle (7:00-19:00) and minimum ventilation of 15 air changes per hr
with standard pellet diet and water. Certificate of analysis for dissolved
materials, heavy metals, pesticide residues, pH, nitrates and nitrites
were periodically supplied. Dosage and dose volumes of G. africana
administered to animals are shown in Table 1. Clinical signs were re-
corded daily, body weights were recorded weekly, and necropsies were
performed on day 15. Animals were euthanized by exposure to an in-
creasing concentration of carbon dioxide and major blood vessels were
cut to exsanguinate. Necropsy consisted of an examination of the cra-
nial, thoracic and abdominal organs and tissues in situ. Carcasses were
discarded after this procedure.
2.4. Statistical analysis and electronic data capture software used
No formal statistical analysis was carried out. Test item/control
formulation: Dispense version 7.0.3.7 was used to electronically cap-
ture the data.
2.5. Acute dermal toxicity study
The acute dermal toxicity test was conducted in accordance with the
OECD guideline No. 402 for chemical testing [22,23]. It was conducted
to assess the adverse effects that may occur within a short time period
following a single dermal administration of G. africana extract. Dermal
administration was chosen because it is potential route of accidental
human exposure and allows hazard classification to be evaluated.
Briefly, Sprague Dawley rats, approximately 8 weeks old, comprising 5
males (291–301 g) and 5 females (182–190 g) were used. The standard
maintenance conditions of animals were similar to those of conducted
in the acute toxicity study. G. africana was applied at a dose of
2000mg/kgbw to sites representing approximately 10% of the total
body surface area on the shaved backs of five male and five female
Table 1
Dosage and dose volume of G. africana administered to animals in different
groups.
Group Dosage (mg/kgbw) Dose volume (ml/kgbw) Animals
1 300 0.34 1–3
2 2000 2.27 4–6
3 2000 2.27 7–9
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Sprague-Dawley rats. Application sites were covered with semi-occlu-
sive dressings for 24 h. After the 24 h contact period, the patches were
removed, the dosing sites were demarcated and the skin was wiped
with water. This was followed by a 14 day observation period. Clinical
signs were also recorded daily, body weights were recorded weekly,
and necropsies were performed on day 15. Animals were euthanized by
exposure to an increasing concentration of carbon dioxide and major
blood vessels were cut to exsanguinate. The mean doe volumes applied
to the surfaces of the animals are shown in Table 2.
2.6. Statistical analysis and electronic data capture software used
No formal statistical analysis was carried out. Dose formulation:
Dispense version 7.0.3.7 was used to electronically capture the data.
2.7. SkinEthic Episkin skin irritation assay
The SkinEthic Episkin irritation assay was conducted in accordance
with OECD 439 [24]. This skin irritation assay was used to measure the
skin irritation potential of G. africana by assessing the cytotoxic effects
after a specific exposure period and recovery time. The endpoint of this
assay was the estimation of the cell viability by evaluating the ability of
the cells to reduce the MTT to its formazan metabolite via mitochon-
drial reductase. Prior to conducting the irritation assay, G. africana was
tested to determine if it was capable of reducing (MTT) to its formazan
metabolite. 10 μl G. africana was added to 2ml MTT (approximately
0.3 mg/ml) in PBS in a glass universal vial (three replicates) and in-
cubated at 37 °C in a humidified atmosphere with 5% CO2 for ap-
proximately 3 h. Formazan production was assessed by visual inspec-
tion. Three replicates of the positive control (eugenol, 10 μl) and
negative control (sterile, ultra-pure water, 10 μl) were tested in parallel
to demonstrate the efficacy of the MTT solution. Briefly, 10 μl of the
concentrated extract (20% (w/v) and the in-use dilution (concentrate
diluted to 1% v/v in sterile ultra-pure water) were applied onto the
exposed surface of three viable Episkin reconstructed human epidermis
units for 15min. The extract was then washed off and the units placed
in an incubator (37 °C in a humidified atmosphere with 5% CO2) for a
recovery period of 42 h. After the recovery period, the skin units were
transferred to assay medium containing MTT (0.3 mg/ml) and returned
to the incubator for 3 h. Biopsies of the Episkin membranes were then
removed and added to isopropanol. The formazan production was as-
sessed by measuring absorbance at 550 nm and the viability of each
individual tissue calculated as a percentage of the mean negative con-
trol viability. The test substance was considered to be an irritant to the
skin if the tissue viability after exposure and post-treatment incubation
was less than or equal to 50%. Furthermore, the test substance was
considered as “no category” if the tissue viability after exposure and
post-treatment incubation was more than 50% (depending on country/
regional regulatory requirements) as stipulated by the OECD.
2.8. Dermal sensitization test using the local lymph node assay (LLNA)
The local lymph node assay (LLNA) was conducted in accordance
with the OECD test guideline No. 429 [25]. This study examined the
delayed contact hypersensitivity or the dermal sensitization potential of
G. africana in CBA/Ca mice. Briefly, Twenty-two female (nulliparous
and non-pregnant) CBA/Ca mice (7–8 weeks old and 16–20 g) were
used. Animals were maintained under the following conditions average
daily temperatures of 19–21 °C, average daily relative humidity
54–70%, lighting 12 h light/dark cycle (7:00-19:00) and ventilation
minimum of 15 air changes per hr. The same diet and water as that used
in the acute dermal and oral toxicity studies was used in this study. G.
africana concentrations (50 and 100mg/ml) were prepared by diluting
the stock (G. africana concentrate) with dimethyl formamide (DMF)
(vehicle). G. africana (50, 100 and 200mg/ml) and the vehicle control
(DMF) were applied to the dorsal surfaces of both ears (25 μl/ear) of
female CBA mice (5 per group) once daily for three days. Hexyl cin-
namicaldehyde was used as a positive control at concentrations of 5%,
10% and 25%. The findings of a preliminary study showed that
200mg/ml of G. africana caused no significant irritation. All animals
were observed daily for signs of toxicity. Treatment sites were scored
for irritation on day 3. Body weights were recorded on days1 (pre-dose)
and 6. Three days after the last treatment, animals were administered
with 3h-methyl thymidine (20 μCi, iv). After 5 h, the animals were
euthanized by exposure to increasing concentrations of carbon dioxide.
The major blood vessels were then severed and the auricular lymph
nodes were excised. Pooled lymph node cell suspensions from each
animal were prepared, washed with phosphate-buffered saline (PBS),
and treated overnight with 5% trichloroacetic acid (TCA) at 2–8 °C for
approximately 19 h to precipitate DNA. DNA was recovered by cen-
trifugation, resuspended in TCA, transferred to10ml scintillation fluid,
and measured for radioactivity (Packard 2800TR scintillation counter).
Stimulation indices were calculated by dividing the mean dpm (disin-
tegrations per minute) for each G. africana treatment group by the mean
dpm for the vehicle control group. A stimulation index of 3 or greater
was interpreted as evidence that the test substance was a dermal sen-
sitizer. Treatment groups with the vehicle and G. africana formulations
are shown in Table 3.
3. Results
3.1. Acute oral toxicity study
Results of the acute oral toxicity study are summarized in Table 4.
There were no unscheduled deaths among animals receiving G. africana
extract at either 300 or 2000mg/kgbw dosage. At necropsy, macro-
scopic examination on day 15 revealed no abnormalities in any animal.
There were no adverse signs of reaction to treatment at a dose of 300 or
2000mg/kgbw. According to the OECD guidelines, the weight range for
female rats is 200–300 g. This range is suggested to provide animals of a
size which facilitates the test to be conducted. In addition, the OECD
guidelines state that the weight of the animals must fall within an in-
terval of± 20% of the mean weight of any previously dosed animals.
Since the weight of the animals was within the stipulated range, the
body weight gain was considered to be acceptable for rats of this age
and strain.
3.2. Acute dermal toxicity study
Key findings of the acute dermal toxicity study are summarized in
Table 5. There were no unscheduled deaths during the observation
period. There were no systemic signs of toxicity recorded in any animal
at any observation time point. At necropsy, females on day 15 revealed
no macroscopic abnormalities. Among males, enlargement of
Table 2
Mean dose volumes of G. africana application based on body surface areas.
Sex Mean dose (ml) Body surface covered (%) Dosage (mg/cm2)
Males 0.78 6 29
Females 0.55 7 20
Table 3
Treatment of animals with the vehicle and formulations of G. africana.
Group Treatment Formulation concentration (mg/ml/
kgbw)
Animal
1 Dimethylformamide 0 1–5
2 G. africana extract 50 6–10
3 G. africana extract 100 11–15
4 G. africana extract 200 16–20
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mandibular lymph nodes was recorded in 4 of the 5 animals. Other
macroscopic abnormalities included dark and/or pale foci in lungs in 3
males, and intestinal abnormalities such as pale appearance and/or
abnormal contents of the jejunum in 2 males. In addition, there were
single instances of reddening of the lungs, prominence of Peyer’s patch,
speckling of the thymus and distension of the ileum. However, these
necropsy findings are commonly observed background findings in rats
of this strain and are not considered as a result of dermal application of
G. africana extract. Under the study conditions, the mean lethal oral and
dermal dosage (LD50) of G. africana extract in Sprague-Dawley rats was
considered to exceed 2000mg/kgbw.
3.3. SkinEthic EpiSkin® skin irritation assay
Key findings of the skin irritation study are summarized in Table 6.
The results of the assay were similar for viable Episkin units dosed with
the concentrated G. africana extract. The G. africana concentrate (20%
(w/v) resulted in a mean Episkin viability of 84.75%±11.26% of the
negative control value. The results of the assay were similar for all vi-
able units dosed with G. africana (in-use dilution 1% (v/v)). The G.
africana extract (in-use dilution) resulted in a mean Episkin viability of
92.97%±14.63% of the negative control value. Based on these find-
ings, G. africana extract (concentrate and in-use dilution) was judged to
be non-irritant (no category).
3.4. Dermal sensitization test using the local lymph node assay (LLNA)
Key findings from the local lymph node assay in mice are sum-
marized in Table 7. G africana caused no systemic signs of toxicity.
There was no effect of treatment on body weight. Although body weight
losses were recorded in 4 of the 20 mice, they were restricted to animals
treated with either the 25% or 50% concentrations. There were no body
weight losses among control mice or mice treated with undiluted G.
africana extract. The stimulation indices for mice treated with the G.
africana extract at concentrations of 25%, 50% and 100% were 1.3, 0.9
and 1.3, respectively. Open application of G. africana extract at the
given concentrations did not result in a stimulation index of greater
than 3 in any group. G. africana was considered not to have the po-
tential to cause dermal sensitization.
4. Discussion
The use of natural medicines for the treatment of various ailments
has increased over the years. This is attributed to them being con-
sidered safer alternatives with less side effects in comparison to syn-
thetic pharmaceuticals [26]. As a result, extensive studies are underway
to evaluate the development and use of traditional medicines in ad-
vancing their effectiveness and safety [27]. Nonetheless, inadequate
scientific data on dosing, quality, toxicity, safety and efficacy of various
traditional medicine formulations are available [27–29]. Toxicity
testing is vital as it facilitates the evaluation of the possible harmful side
effects attributed to these products. Since a number of substances
provoke allergic contact dermatitis in humans, assessment of safety by
carrying out skin sensitization tests is crucial. Furthermore, it is
Table 4







Body weight, g (day 1) 201 ± 4 (3) 204 ± 5 (3) 221 ± 7 (3)
Body weight, g (day 8) 233 ± 10 (3) 240 ± 10 (3) 248 ± 4 (3)
Body weight, g (day
15)
252 ± 6 (3) 260 ± 3 (3) 255 ± 12 (3)
Body weight, gain g
(day 1-15)
51 56 35
Daily observationsb NAD NAD NAD
Necropsyb NAD NAD NAD
The body weights of each individual animal were recorded before dosing on
Day 1 and on Days 8 and 15.
a Except for daily observations and necropsy, all values are means ± SD (N).
b NAD- no abnormalities detected.
Table 5
Acute dermal toxicity study in Sprague-Dawley rats- key findings.a
Males Females
2000mg/kgbw 2000mg/kgbw
Body weight, g (day 1) 339 ± 11(5) 239 ± 13(5)
Body weight, g (day 8) 375 ± 21 (5) 251 ± 17 (5)
Body weight, g (day 15) 413 ± 33 (5) 267 ± 19 (5)
Body weight, gain g (day
1-15)
74 ± 30 (5) 28 ± 0 (5)
Daily observationsb NAD NAD
Necropsyb NAD
Mandibular lymph nodes
Animal 1 Enlarged (14×8 x 2mm)
Animal 2 Enlarged (11×7 x 2mm)
Animal 3 Enlarged (14×8 x 2mm)
Animal 5 Enlarged (11×6 x 2mm)
Lungs
Animal 1 Reddened, all lobes
Many dark foci, all lobes (red,
pinpoint appearance)
Many pale foci, all lobes (cream,
≤ 3mm diameter)
Animal 2 Dark focus, left lobe (red, 3mm
diameter)
Animal 4 3 dark foci, left lobe (red, 1 mm
diameter)
Intestines
Animal 2 Jejunum- pale
Peyer’s patch- prominent
Animal 4 Jejunum-pale, with abnormal
(white) contents





a Except for daily observations and necropsy, all values are means ± SD (N).
b NAD- no abnormalities detected.
Table 6
Skin irritation study results using the episkin test system.a
Treatment group
G. africana 20% G. africana 1% Negative control Positive control
Direct MTT No colour change after 3 h
incubation
No colour change after 3 h
incubation
No colour change after 3 h
incubation
Immediate colour change (dark blue/
purple)
Optical density 0.757 ± 0.101 0.831 ± 0.131 0.894 ± 0.033 0.126 ± 0.064
% viability 84%±11.26 92.97%±14.63 100%±3.70 14.10%±7.76
a Except for the direct MTT, all values are means ± SD.
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imperative to evaluate the short or long term effects of these products
on human health [26,30].
The studies described in this article were performed to evaluate the
toxicity of G. africana extract. G. africana was virtually non-toxic (lethal
dose greater than 2000mg/kgbw) following single oral administration
to female Sprague-Dawley rats. Adverse effects of G. africana were ac-
cessed by evaluating body weight and through necropsy. All clinical
signs, parameters and behaviours were normal with no lesions of in-
ternal organs. No signs of toxicity and no mortality were observed.
Additionally, G. africana was non-toxic (lethal dose greater than
2000mg/kgbw) following single, 24 h, dermal administration to female
and male Sprague-Dawley rats. There were no findings at necropsy that
were considered to be related to treatment. Hence, the necropsy find-
ings seen in males are commonly observed background findings in rats
of this strain. The concentrated G. africana extract as well as the in-use
dilution were considered as being non-irritant to the skin. Exposure to
the concentrated extract and in-use dilution resulted in episkin vi-
abilities of 84.75%±11.26% and 92.97%±14.63% respectively. The
negative and positive controls were within the defined acceptance cri-
teria and demonstrated the efficacy of the test system. In the dermal
sensitization studies, G. africana did not have the potential to cause
sensitization. At the time of the study, no data pertaining to the po-
tential of G. africana components to cause local irritation in mice, rats
or skin was available. The LLNA showed that at the highest (undiluted)
concentration, the extract had no toxic effects. In addition, it did not
elicit a hypersensitivity reaction in the mice. No concentration resulted
in a stimulation index of ≥ 3 in any group. Consequently, it was es-
tablished that the test item did not have the potential to cause sensi-
tization. These studies were performed in accordance with the OECD
guidelines and Principles of Good Laboratory Practice.
Environmental toxicology studies of G. africana extracts have been
found to have a variety of inhibitory effects (EC50) against Vibrio fischeri
(0.7 μg/ml, 30min), Selenastrum capricornatum (100 μg/ml, 72 h),
Daphnia pulex (30 μg/ml, 48 h) and Poecilia reticulate (20 μg/ml 96 h)
[19]. The minimum inhibitory concentrations for various fungal pa-
thogens (Alternaria, Botrytis, Cylindrocarpon, Eutypa, Fusarium) of plants
showed values ranging from 25 to 100mg/ml [14] and for Myco-
bacterium smegmatis 0.78mg/ml [15]. An immune toxicity study of G.
africana extract found that concentrations of 19 to 500 μg/ml modulate
pro-inflammatory cytokines of BALB/c mouse spleenocytes [20].
This study investigated the delayed contact hypersensitivity poten-
tial, acute oral toxicity, acute dermal toxicity and SkinEthic Episkin in
vitro irritation assay effects of G. africana ethanolic extract. The skin
irritation study found it to be a non-irritant and it was shown to be a
dermal non-sensitizer in the local lymph node assay in mice. Findings
demonstrated that the toxicity profile for G. africana is acceptable for its
intended use in agricultural and medical applications. All tests were
conducted according to the Organization for Economic Co-operation
and Development (OECD).
5. Conclusion
The outcomes of this study demonstrated that the ethanolic extract
of G. africana did not result in any in vivo danger. These findings will be
included in the documentation for a toxicological review to register G.
africana extracts as pesticidal adjuvants and plant growth stimulants.
Nevertheless, pharmacological and biochemical investigations will be
essential in elucidating the mechanism of action and will be beneficial
in utilizing this plant as a therapeutic agent. Furthermore, a detailed
experimental analysis of the chronic toxicities is important to support
these findings. Toxicity assessment of medicinal plants is important in
evaluating their safety and sensitizing potential. Clinical trials have not
yet been performed on this medicinal plant.
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